Skip to main content

Healthcare

Arsenal announces sale of Certara, retains significant minority investment stake

July 11, 2017
Arsenal announces the sale of Certara, the global leader in model-informed (in silico) drug development and regulatory science, focused on optimizing drug development and improving health outcomes
Read More about Arsenal announces sale of Certara, retains significant minority investment stake

TractManager Appoints Trace Devanny Chief Executive Officer

October 27, 2016
TractManager, the leading provider of powerful healthcare strategic sourcing and compliance application suites announced that it has named Trace Devanny Chief Executive Officer of the company.
Read More about TractManager Appoints Trace Devanny Chief Executive Officer

Arsenal Capital Partners Hires Spaight As Healthcare Operating Partner

October 17, 2016
Spaight Previously Served as Chairman and Chief Executive Officer of WIL Research Company, Inc.
Read More about Arsenal Capital Partners Hires Spaight As Healthcare Operating Partner

Arsenal Capital-Led Investor Group Recapitalizes WIRB-Copernicus Group

August 18, 2016

NEW YORK, August 18, 2016 – Arsenal Capital Partners, a New York based private equity firm, announced today that its portfolio company WIRB-Copernicus Group® (WCG™), has completed a recapitalization in which Arsenal Capital Partners led an investment group, including Arsenal Capital Fund IV,  MSD Capital, L.P. and other leading institutional investors, to provide WCG with additional capital to continue its successful growth.

Read More about Arsenal Capital-Led Investor Group Recapitalizes WIRB-Copernicus Group

Arsenal Capital Partners Invests In BioreclamationIVT

January 19, 2016
BioIVT is the leading provider of biological and in vitro products to the pharmaceutical, diagnostic, and biotechnology organizations. BioIVT’s products are used in drug discovery, biomarker, toxicology, bioanalytical and ADME research. The company’s products and value added services enable its clients to significantly reduce the time and expense of bringing new drugs and diagnostics to market.
Read More about Arsenal Capital Partners Invests In BioreclamationIVT
Subscribe to Healthcare